These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32355541)

  • 1. Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.
    Santana-Rivera Y; Rabelo-Fernández RJ; Quiñones-Díaz BI; Grafals-Ruíz N; Santiago-Sánchez G; Lozada-Delgado EL; Echevarría-Vargas IM; Apiz J; Soto D; Rosado A; Meléndez L; Valiyeva F; Vivas-Mejía PE
    Am J Transl Res; 2020; 12(4):1275-1292. PubMed ID: 32355541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Noriega Rivera RA; Rivera YS; Tous-Beveraggi J; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic analysis of N-glycomic and transcriptomic changes in the development of ovarian cancer cell line A2780 to its three cisplatin-resistant variants.
    Lin G; Zhao R; Wang Y; Han J; Gu Y; Pan Y; Ren C; Ren S; Xu C
    Ann Transl Med; 2020 Mar; 8(6):289. PubMed ID: 32355733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78.
    Li W; Wang W; Dong H; Li Y; Li L; Han L; Han Z; Wang S; Ma D; Wang H
    Oncol Rep; 2014 Jun; 31(6):2525-34. PubMed ID: 24756776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells.
    Lee RX; Li QQ; Reed E
    Anticancer Res; 2012 Aug; 32(8):3103-13. PubMed ID: 22843880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer.
    Qian X; Xu W; Xu J; Shi Q; Li J; Weng Y; Jiang Z; Feng L; Wang X; Zhou J; Jin H
    Oncotarget; 2017 Jul; 8(29):47691-47708. PubMed ID: 28548950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
    Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
    Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-18a-5p Suppresses Tumor Growth
    Quiñones-Díaz BI; Reyes-González JM; Sánchez-Guzmán V; Conde-Del Moral I; Valiyeva F; Santiago-Sánchez GS; Vivas-Mejía PE
    Front Oncol; 2020; 10():602670. PubMed ID: 33392094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer.
    Reyes-González JM; Quiñones-Díaz BI; Santana Y; Báez-Vega PM; Soto D; Valiyeva F; Marcos-Martínez MJ; Fernández-de Thomas RJ; Vivas-Mejía PE
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
    Brown R; Clugston C; Burns P; Edlin A; Vasey P; Vojtĕsek B; Kaye SB
    Int J Cancer; 1993 Oct; 55(4):678-84. PubMed ID: 8406999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
    Yunmbam MK; Guo Y; Miller MR; Yu JJ
    Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis.
    Qin Y; Li W; Long Y; Zhan Z
    Cancer Biomark; 2019; 24(4):469-475. PubMed ID: 30932883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma.
    Tasaka R; Fukuda T; Shimomura M; Inoue Y; Wada T; Kawanishi M; Yasui T; Sumi T
    Oncol Lett; 2018 Mar; 15(3):3085-3090. PubMed ID: 29435041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.
    Li B; Gao Y; Rankin GO; Rojanasakul Y; Cutler SJ; Tu Y; Chen YC
    Cancer Lett; 2015 Jan; 356(2 Pt B):418-33. PubMed ID: 25304379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.